The Stock Connect Innovative Drug ETF E Fund (159316) attracted over 1.8 billion in the past month, with the underlying index rising 2.6% in the afternoon, aiming for a 4-day winning streak.

As of 13:11, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 2.6%, aiming for a four-day winning streak; among its constituent stocks, Innovent Biologics rose 1.32%, BeiGene rose 2.26%, CSPC Pharmaceutical Group rose 0.35%, Akeso rose 3.44%, China National Pharmaceutical Group rose 1.62%, Hansoh Pharmaceutical rose 1.26%, Simcere Pharmaceutical rose 2.56%, Kelun-Biotech rose 4.04%, Zai Lab rose 15%, and Concert Pharmaceuticals-B rose 5.46%.

The Stock Connect Innovative Drug ETF E Fund (159316) continues to see capital inflows. As of the previous trading day, the fund had a net inflow of 94.342 million yuan over the past week, 1.807 billion yuan over the past month, and 6.853 billion yuan over the past year.

In terms of news, according to Medicine Cube, from July 27 to August 2, the Center for Drug Evaluation of the National Medical Products Administration disclosed 119 clinical trial registration records, of which 36 were new clinical trial registrations for innovative drugs at Phase II or later stages.

Regarding performance, BeiGene achieved revenue of 22.22 billion yuan in the first half of the year, with net profit attributable to shareholders increasing significantly by more than six times year-on-year; Innovent Biologics' product revenue exceeded 8.2 billion yuan in the first half of the year, a year-on-year increase of over 55%. RemeGen is expected to achieve a net profit attributable to shareholders of approximately 4.7 billion yuan in the first half of the year, turning a profit compared to the same period last year.

East Money Securities analysis points out that innovative drug companies are shifting from "telling BD stories" to "clinical data + commercialization realization." The transaction volume of Chinese innovative drug License-outs in the first half of 2026 is approaching the total volume of the previous year, with frequent large platform deals enhancing bargaining power. Allocation should focus on mature pipelines with clear global clinical progress and imminent domestic volume growth, avoiding valuation overdrafts for pure concept assets.

The management fee rate for the Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fees can effectively reduce cost expenditures for investors.

The Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize this round of investment opportunities in Hong Kong stock innovative drugs.

E Fund Management is a leading comprehensive asset management institution in China, with over 20 years of professional accumulation in index investment. The index product line comprehensively covers mainstream broad-based indices, involving multiple industry indices, covering cross-border and cross-market indices, reaching more than 10 exchanges globally. The professional index investment research team possesses rich experience in product design and investment management.